- Home
- LZ vs TARS Comparison
LZ vs TARS Comparison
Compare LZ & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- TARS
- Stock Information
- Founded
- LZ 2001
- TARS 2016
- Country
- LZ United States
- TARS United States
- Employees
- LZ N/A
- TARS N/A
- Industry
- LZ EDP Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- LZ Technology
- TARS Health Care
- Exchange
- LZ Nasdaq
- TARS Nasdaq
- Market Cap
- LZ 1.5B
- TARS 1.7B
- IPO Year
- LZ 2021
- TARS 2020
- Fundamental
- Price
- LZ $8.78
- TARS $40.95
- Analyst Decision
- LZ Hold
- TARS Strong Buy
- Analyst Count
- LZ 9
- TARS 7
- Target Price
- LZ $8.64
- TARS $67.14
- AVG Volume (30 Days)
- LZ 1.8M
- TARS 597.8K
- Earning Date
- LZ 08-06-2025
- TARS 08-07-2025
- Dividend Yield
- LZ N/A
- TARS N/A
- EPS Growth
- LZ 72.11
- TARS N/A
- EPS
- LZ 0.17
- TARS N/A
- Revenue
- LZ $690,777,000.00
- TARS $233,674,000.00
- Revenue This Year
- LZ $8.18
- TARS $122.94
- Revenue Next Year
- LZ $7.23
- TARS $44.14
- P/E Ratio
- LZ $51.64
- TARS N/A
- Revenue Growth
- LZ 3.25
- TARS 449.03
- 52 Week Low
- LZ $5.33
- TARS $20.08
- 52 Week High
- LZ $10.60
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- LZ 44.92
- TARS 40.57
- Support Level
- LZ $8.45
- TARS $39.33
- Resistance Level
- LZ $8.83
- TARS $42.00
- Average True Range (ATR)
- LZ 0.19
- TARS 1.73
- MACD
- LZ -0.08
- TARS 0.05
- Stochastic Oscillator
- LZ 20.83
- TARS 17.95
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.